
What we're looking for:
Early Detection and Intervention: Implement new tools that can help clinicians recognize and act on early, subtle symptoms and nodules leading to quicker, more effective diagnoses.
Integrated Care Pathways: Solutions that create seamless, integrated workflows that connect primary care physicians and specialists. These tools can guide them through the entire process, from first symptoms to referral, imaging, and molecular testing.
Increase Biomarker Testing Rates: Integrate biomarker testing as a critical part of diagnosis, especially in community healthcare settings, to ensure broader patient access to personalized treatments.
Enhance Clinical Decision Support: Integrate real-time clinical decision tools directly into existing EMRs. This could involve creating prompts and flags for at-risk patients and embedding the latest guidelines to help clinicians at the point of care.
Bridging Educational Gaps: Tools that support clinicians to be fully aware of updated guidelines for early detection, screening eligibility, or biomarker-directed therapy.
Eligibility
-
Regulatory: FDA-cleared, CE-marked, or equivalent or in advanced stages of submission are preferred. Commercial-stage product or clinical deployment underway
-
HIPAA/GDPR compliant
-
Willingness to co-develop or scale with biopharma



